Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcus Biosciences Inc (NY: RCUS ) 15.99 -0.21 (-1.30%) Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 980,892 Open 16.20 Bid (Size) 15.66 (22) Ask (Size) 17.12 (1) Prev. Close 16.20 Today's Range 15.35 - 16.20 52wk Range 12.95 - 25.47 Shares Outstanding 90,900,000 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Arcus Biosciences Announces New Employment Inducement Grants June 11, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers June 10, 2024 From Arcus Biosciences Via Business Wire Performance YTD -18.75% -18.75% 1 Month -4.71% -4.71% 3 Month -8.58% -8.58% 6 Month -6.44% -6.44% 1 Year -15.62% -15.62% More News Read More Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 06, 2024 From Arcus Biosciences Via Business Wire Navigating 5 Analyst Ratings For Arcus Biosciences March 25, 2024 Via Benzinga Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know February 22, 2024 Via Benzinga Recap: Arcus Biosciences Q4 Earnings February 21, 2024 Via Benzinga Earnings Scheduled For February 21, 2024 February 21, 2024 Via Benzinga After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies June 03, 2024 Via Benzinga Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer June 02, 2024 From Gilead Sciences, Inc. Via Business Wire Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers June 01, 2024 From Gilead Sciences, Inc. Via Business Wire Preview: Arcus Biosciences's Earnings February 20, 2024 Via Benzinga Arcus Biosciences Announces New Employment Inducement Grants May 24, 2024 From Arcus Biosciences Via Business Wire 12 Health Care Stocks Moving In Friday's Pre-Market Session May 24, 2024 Via Benzinga Arcus Biosciences Announces New Employment Inducement Grants May 09, 2024 From Arcus Biosciences Via Business Wire RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update May 08, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024 May 02, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting April 24, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update April 23, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Announces New Employment Inducement Grants April 09, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Announces New Employment Inducement Grants March 26, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Announces New Employment Inducement Grants March 11, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences to Participate in Two Upcoming Investor Conferences February 28, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Announces New Employment Inducement Grants February 27, 2024 From Arcus Biosciences Via Business Wire Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update February 21, 2024 From Arcus Biosciences Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
